SangUk Kang - Bridge Biotherapeutics VP Director
| 288330 Stock | KRW 3,940 120.00 2.96% |
Insider
SangUk Kang is VP Director of Bridge Biotherapeutics
| Web | http://bridgebiorx.com |
Similar Executives
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea. Bridge Biotherapeutics (288330) is traded on KOSDAQ in Korea and employs 4 people.Management Performance
| Return On Equity | -75.4 |
Bridge Biotherapeutics Leadership Team
Elected by the shareholders, the Bridge Biotherapeutics' board of directors comprises two types of representatives: Bridge Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bridge. The board's role is to monitor Bridge Biotherapeutics' management team and ensure that shareholders' interests are well served. Bridge Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bridge Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Taeksang Park, VP CFO | ||
| Gwanghee Lee, VP Director | ||
| SangUk Kang, VP Director | ||
| James Lee, CEO Director |
Bridge Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bridge Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -75.4 | |||
| Current Valuation | 29.26 B | |||
| Shares Owned By Insiders | 30.27 % | |||
| Shares Owned By Institutions | 9.09 % | |||
| Revenue | 1.92 B | |||
| Gross Profit | (1.12 B) | |||
| EBITDA | (21.27 B) | |||
| Net Income | (26.28 B) | |||
| Cash And Equivalents | 8.2 B | |||
| Total Debt | 53.63 M |
Pair Trading with Bridge Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bridge Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bridge Stock
Moving against Bridge Stock
| 0.56 | 041510 | SM Entertainment | PairCorr |
| 0.56 | 032640 | LG Uplus | PairCorr |
| 0.54 | 035420 | Naver | PairCorr |
| 0.39 | 078160 | MEDIPOST | PairCorr |
| 0.36 | 011390 | Busan Industrial | PairCorr |
The ability to find closely correlated positions to Bridge Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bridge Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bridge Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bridge Biotherapeutics to buy it.
The correlation of Bridge Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bridge Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bridge Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bridge Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Bridge Stock
Bridge Biotherapeutics financial ratios help investors to determine whether Bridge Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bridge with respect to the benefits of owning Bridge Biotherapeutics security.